Smacked again: Protalix plummets on FDA delay of Gaucher's drug NDA
This article was originally published in Scrip
Executive Summary
Shares of Protalix BioTherapeutics plunged as low as 22% on 6 December after the firm said the US FDA extended its review by three months of the new drug application (NDA) for the company’s experimental Gaucher's disease drug taliglucerase alfa – delaying the Prescription Drug User Fee Act (PDUFA) action date until 1 May 2012.